Camber Pharmaceuticals Launches Generic Toviaz®

Press Release
Article

Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets.

Piscataway, NJ, April 17, 2024–Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets.

According to the Cleveland Clinic, approximately 33 million Americans struggle with overactive bladders, impacting about 30% of adult males and 40% of adult females nationwide.

Fesoterodine Fumarate ER Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.

Fesoterodine Fumarate ER Tablets are available in 30 count bottles in 4 mg and 8 mg strengths.

To learn more about Fesoterodine Fumarate Extended- Release Tablets, please visit https://www.camberpharma.com/products/fesoterodine-fumarate-er/

Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.

Related Videos
Video 9 - "Unmet Needs in Relapsed or Refractory Multiple Myeloma"
Video 8 - "Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting"
Video 7 - "Role of Pharmacists in Operationalizing Bispecific Antibodies"
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
A panel of 3 experts on hepatic encephalopathy
A panel of 5 experts on ASCVD
A panel of 4 experts
A panel of 4 experts
A panel of 4 experts
A panel of 4 experts
© 2024 MJH Life Sciences

All rights reserved.